InflaRx (NASDAQ:IFRX) Upgraded at Raymond James Financial

InflaRx (NASDAQ:IFRX) was upgraded by investment analysts at Raymond James Financial from an “outperform” rating to a “strong-buy” rating in a report released on Wednesday, Marketbeat.com reports. The firm presently has a $9.00 target price on the stock. Raymond James Financial’s target price suggests a potential upside of 270.37% from the company’s current price.

A number of other brokerages have also recently commented on IFRX. Wall Street Zen raised InflaRx from a “sell” rating to a “hold” rating in a research report on Saturday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of InflaRx in a research report on Friday, March 27th. Cantor Fitzgerald lifted their price objective on InflaRx from $2.00 to $4.00 and gave the company an “overweight” rating in a research note on Monday. Oppenheimer began coverage on InflaRx in a report on Friday, April 24th. They issued an “outperform” rating and a $5.00 target price on the stock. Finally, HC Wainwright raised their price target on InflaRx from $6.00 to $8.00 and gave the company a “buy” rating in a report on Monday. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $7.00.

InflaRx Price Performance

NASDAQ:IFRX opened at $2.43 on Wednesday. The firm’s 50-day moving average price is $1.29 and its 200-day moving average price is $1.16. The company has a market capitalization of $175.66 million, a PE ratio of -3.42 and a beta of 2.42. InflaRx has a 1-year low of $0.71 and a 1-year high of $2.95.

InflaRx (NASDAQ:IFRX) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.08. Equities analysts anticipate that InflaRx will post -0.59 EPS for the current fiscal year.

Institutional Investors Weigh In On InflaRx

A number of large investors have recently added to or reduced their stakes in the stock. Cubist Systematic Strategies LLC lifted its holdings in shares of InflaRx by 33.9% during the 1st quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company’s stock valued at $31,000 after buying an additional 7,616 shares during the period. Woodline Partners LP bought a new position in InflaRx in the first quarter valued at about $766,000. Adage Capital Partners GP L.L.C. purchased a new position in InflaRx in the second quarter worth about $262,000. Squarepoint Ops LLC grew its stake in shares of InflaRx by 29.1% during the 3rd quarter. Squarepoint Ops LLC now owns 188,523 shares of the company’s stock valued at $253,000 after purchasing an additional 42,489 shares during the period. Finally, ADAR1 Capital Management LLC bought a new stake in shares of InflaRx during the 3rd quarter valued at about $214,000. Institutional investors own 42.39% of the company’s stock.

About InflaRx

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.